HOME >> BIOLOGY >> NEWS
Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack

San Diego, CA, September 27, 2004 - MacroPore Biosurgery, Inc. (Frankfurt: XMP) today announced that adipose tissue-derived regenerative cells improved heart function following myocardial infarction in a large-animal preclinical safety study. This study, performed in swine, confirms previous preclinical work by MacroPore Biosurgery and others suggesting that the Company's proprietary, patented technology is safe and may be clinically useful in treating heart disease. The goal of the study was to determine the safety of adipose tissue-derived regenerative cells delivered into coronary circulation without cell culture. The results were presented in a poster presentation at the Transcatheter Cardiovascular Therapeutics 2004 meeting in Washington D.C. (Abstract # 550778).

Intracoronary infusion of adipose tissue-derived regenerative cells 48 hours after infarction was found to be safe, with all 13 swine surviving to the 6-month follow-up period. Additionally, the study demonstrated a statistically significant improvement in left ventricular ejection fraction (LVEF) at six-months post-infarction in the treated group over the control group, as measured by 2D echocardiography. Similar trends were observed by measuring LVEF via cineangiography, as provided in the data table below. LVEF is a measure of the heart's ability to pump oxygenated blood throughout the body. It specifically determines the fraction of blood that is ejected out of the left ventricle with each contraction.

"We are encouraged by the findings from this preclinical study, which suggest that delivery of autologous, adipose tissue-derived, regenerative cells is safe and effective in preserving left ventricular systolic function," said John K. Fraser, Vice President, Research and Technology, of MacroPore Biosurgery. "Despite the fact that this study was designed primarily to evaluate the safety of dose escalation in limited infarcts, we observed statistically significant improvements in h
'"/>

Contact: Tom Baker
tbaker@macropore.com
858-232-7234
Cytori Therapeutics
27-Sep-2004


Page: 1 2 3

Related biology news :

1. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
2. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
3. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
4. Plant pathologists meeting in Anaheim, CA to discuss agricultural security, food safety, and more
5. Plant pathologists to meet in Anaheim, CA to discuss agricultural security, food safety, and more
6. Invention could improve PVC safety and strengthen $1.8-billion industry worldwide
7. Educational program increases some safety behaviors for older drivers
8. UNC study may improve gene therapy safety
9. Risk and food are on the same plate: World food safety experts offer new methods to assess risk
10. Study explores safety of low-dose radiation
11. Americans knowledge of genetically modified foods remains low and opinions on safety still split

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/19/2020)... Conn. (PRWEB) , ... March 17, 2020 , ... ... develops tools for characterizing microbiome populations down to the strain level, recently unveiled ... The Shoreline Wave amplicon kit contains the same innovative amplification capabilities as the ...
(Date:3/13/2020)... (PRWEB) , ... March 13, 2020 , ... ... agreement with Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s ... marketing, and medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) ...
(Date:3/9/2020)... ... March 09, 2020 , ... Application transformation ... as enterprises sought to achieve competitive advantage by transforming their core applications, ... transformation efforts delivered the intended consequences. , Application transformation refers to the ...
Breaking Biology News(10 mins):
(Date:4/1/2020)... Calif. (PRWEB) , ... March 31, 2020 , ... Carterra® ... Institute for Immunology (LJI), announced today that they will use Carterra’s proprietary LSA™ platform ... therapeutic candidates to the clinic as early as this summer. , La Jolla ...
(Date:3/27/2020)... ... 2020 , ... iFirst Medical Technologies, Inc., a leader in handheld diagnostic devices, ... "COVID-19 poses a grave danger to public health here in the U.S. and around ... act. Broad-based testing and on-the-spot results promise to slow the spread and save human ...
(Date:3/13/2020)... ... March 12, 2020 , ... ... APC Microbiome Ireland SFI Research Center (APC), a pioneer in the field of ... and play a significant role in human health, based at University College Cork ...
(Date:3/10/2020)... , ... March 10, 2020 ... ... full-service cold chain biopharmaceutical engineering firm, is pleased to announce the addition ... on combination medical device qualification and validation in the biopharmaceutical cold chain. ...
Breaking Biology Technology:
Cached News: